This conversation focuses on MRE Findings that suggest flaws in biopsy as a measurement device and also in fibrosis as a solitary endpoint.

In the rest of the discussion, the group discusses challenges in proving that NITs can accurately measure and differentiate between different drugs in terms of therapeutic efficacy. One challenge is with the current metrics. We speak frequently about the challenges with biopsy and with fibrosis being an ordinal variable, but as Alina notes, being too tied for fibrosis means we focus solely on one measure of improvement and downplay others, such as steatosis.

The conversation about MRE is too rich and nuanced to be captured in a paragraph or two. This episode is worth two or three listens to capture all its points.